No Data
No Data
Xiduo Pharmaceuticals (301130.SZ): Cumulative repurchased 4.9953% of shares.
On August 1st, Gelunhui reported that Xiduo Pharmaceuticals (301130.SZ) has accumulated 4,036,458 shares of the company's stock through a repurchase account and centralized bidding trading method as of July 31, 2024. This represents 4.9953% of the company's total share capital, with a highest filled price of 26.22 yuan/share, a lowest filled price of 20.65 yuan/share, and a total filled amount of 93,418,916.12 yuan (excluding transaction fees). The repurchase meets the requirements of the company's stock repurchase plan and relevant laws and regulations.
Xiduo Pharmaceuticals (301130.SZ): oxaliplatin oxalate tablets selected by the Centralized Procurement Organization of the Alliance for Group Purchasing of Pharmaceuticals are renewed.
On July 12th, Gelunhui announced that Xiduo Pharmaceutical (301130.SZ) recently participated in the renewal work for drug centralized procurement organized by provincial alliances. Escitalopram oxalate (oral sustained-release dosage form) belongs to the category A drugs in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List. As of the disclosure date of the announcement, the oxalate escitalopram tablet produced by the company has successively been selected for the "Guangdong Alliance amoxicillin and other drug centralized procurement of quantity purchase" and the "2024 Hebei National Collective Procurement first, second, and fourth batch of drug expiration renewal purchase projects." The oxalate escitalopram tablet is used for the treatment of depression and
Xipoint Pharmaceutical (301130.SZ) has cumulatively repurchased 4.9953% of its shares.
On July 1, Gelun Hui reported that Xiduo Pharmaceuticals (301130.SZ) had repurchased 4,036,458 shares of the company through a repurchase special securities account and centralized bidding trading method, accounting for 4.9953% of the company's current total share capital, with a highest transaction price of 26.22 yuan/share, a lowest transaction price of 20.65 yuan/share, and a total transaction amount of 93,418,900 yuan (excluding trading fees) as of June 28, 2024.
Xide Pharmaceutical (301130.SZ) plans to distribute 2.6 yuan per 10 shares on June 12th, after the ex-dividend date.
Xidong Pharmaceuticals (301130.SZ) announced that the proposed annual equity distribution for 2023 will be a cash dividend of 2.6 yuan (including tax) per 10 shares to all shareholders. The ex-dividend date is June 12, 2024.
Xiduo Pharmaceuticals (301130.SZ) has repurchased a total of 3.8217 million shares, costing 88.5031 million yuan.
Xiduo Pharmaceuticals (301130.SZ) announced that as of May 31, 2024, the company will trade through centralized bidding...
West Point Pharmaceutical (301130.SZ): Currently, biosynthesis related technology is not used in products produced or under development
Gelonghui, May 13 | Xidian Pharmaceutical (301130.SZ) said on the investor interactive platform that the company currently does not use biosynthesis related technology in the products it produces or is developing.
No Data